The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor
Abstract
The molecular basis for the anti-inflammatory property of intravenous gamma globulin (IVIG) was investigated in a murine model of immune thrombocytopenia. Administration of clinically protective doses of intact antibody or monomeric Fc fragments to wild-type or Fcγ receptor–humanized mice prevented platelet consumption triggered by a pathogenic autoantibody. The inhibitory Fc receptor, FcγRIIB, was required for protection, because disruption either by genetic deletion or with a blocking monoclonal antibody reversed the therapeutic effect of IVIG. Protection was associated with the ability of IVIG administration to induce surface expression of FcγRIIB on splenic macrophages. Modulation of inhibitory signaling is thus a potent therapeutic strategy for attenuating autoantibody-triggered inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD
Imbach, P., d'APUZZO, V., Hirt, A., Rossi, E., Vest, M., Barandun, S., Baumgartner, C., Morell, A., Schöni, M., & Wagner, H. P. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92400-4 · Cited by 1,666
van der Meché, F. G. A., Schmitz, P. I. M., & the Dutch Guillain–Barré Study Group* (1992) · New England Journal of Medicine · doi:10.1056/nejm199204233261705 · Cited by 1,143
Dalakas, M. C., Illa, I., Dambrosia, J. M., Soueidan, S. A., Stein, D. P., Otero, C., Dinsmore, S. T., & McCrosky, S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292704 · Cited by 1,136
Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Augmented humoral and anaphylactic responses in FcγRII-deficient mice
Takai, T., Ono, M., Hikida, M., Ohmori, H., & Ravetch, J. V. (1996) · Nature · doi:10.1038/379346a0 · Cited by 826
Self-citationOno, M., Bolland, S., Tempst, P., & Ravetch, J. V. (1996) · Nature · doi:10.1038/383263a0 · Cited by 781
Self-citationSpontaneous Autoimmune Disease in FcγRIIB-Deficient Mice Results from Strain-Specific Epistasis
Bolland, S., & Ravetch, J. V. (2000) · Immunity · doi:10.1016/s1074-7613(00)00027-3 · Cited by 752
Self-citationManipulating the Immune System with Immune Globulin
Oates, J. A., Wood, A. J. J., & Dwyer, J. M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260206 · Cited by 648
Cited by
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Self-citationFcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Self-citationLock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-500 · Cited by 1,669
Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin
Kazatchkine, M. D., & Kaveri, S. V. (2001) · New England Journal of Medicine · doi:10.1056/nejmra993360 · Cited by 1,209
IgG placental transfer in healthy and pathological pregnancies
Palmeira, P., Quinello, C., Silveira-Lessa, A. L., Zago, C. A., & Carneiro-Sampaio, M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/985646 · Cited by 1,037
Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Self-citationInflammatory Mediators and the Failing Heart: Past, Present, and the Foreseeable Future
Mann, D. L. (2002) · Circulation Research · doi:10.1161/01.res.0000043825.01705.1b · Cited by 988
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
Meriggioli, M. N., & Sanders, D. B. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70063-8 · Cited by 894
Burns, J. C., & Glodé, M. P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16814-1 · Cited by 884
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C., & Ravetch, J. V. (2008) · Science · doi:10.1126/science.1154315 · Cited by 849
Self-citationProperties of mouse and human IgG receptors and their contribution to disease models
Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 847
Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
Schwab, I., & Nimmerjahn, F. (2013) · Nature Reviews Immunology · doi:10.1038/nri3401 · Cited by 820
Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
Pelosof, L. C., & Gerber, D. E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0099 · Cited by 773
Protein aggregation diseases: pathogenicity and therapeutic perspectives
Aguzzi, A., & O'Connor, T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3050 · Cited by 762
Myasthenia gravis: past, present, and future
Conti-Fine, B. M., Milani, M., & Kaminski, H. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29894 · Cited by 691
FcγRIV: A Novel FcR with Distinct IgG Subclass Specificity
Nimmerjahn, F., Bruhns, P., Horiuchi, K., & Ravetch, J. V. (2005) · Immunity · doi:10.1016/j.immuni.2005.05.010 · Cited by 660
Self-citationORANGE, J., HOSSNY, E., WEILER, C., BALLOW, M., BERGER, M., BONILLA, F., BUCKLEY, R., CHINEN, J., ELGAMAL, Y., & MAZER, B. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.015 · Cited by 653
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
Self-citationThe function of Fcγ receptors in dendritic cells and macrophages
Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., & Lambrecht, B. N. (2014) · Nature Reviews Immunology · doi:10.1038/nri3582 · Cited by 639
Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway
Anthony, R. M., Kobayashi, T., Wermeling, F., & Ravetch, J. V. (2011) · Nature · doi:10.1038/nature10134 · Cited by 633
Self-citationRoles of Fc receptors in autoimmunity
Takai, T. (2002) · Nature Reviews Immunology · doi:10.1038/nri856 · Cited by 626
Follicular B helper T cells in antibody responses and autoimmunity
Vinuesa, C. G., Tangye, S. G., Moser, B., & Mackay, C. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1714 · Cited by 624
Mouse and human FcR effector functions
Bruhns, P., & Jönsson, F. (2015) · Immunological Reviews · doi:10.1111/imr.12350 · Cited by 579
Identification of a receptor required for the anti-inflammatory activity of IVIG
Anthony, R. M., Wermeling, F., Karlsson, M. C. I., & Ravetch, J. V. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810163105 · Cited by 547
Self-citationFcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications
Smith, K. G. C., & Clatworthy, M. R. (2010) · Nature Reviews Immunology · doi:10.1038/nri2762 · Cited by 543
Passive antibody therapy for infectious diseases
Casadevall, A., Dadachova, E., & Pirofski, L.-A. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro974 · Cited by 531
Anti-Inflammatory Actions of Intravenous Immunoglobulin
Nimmerjahn, F., & Ravetch, J. V. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090232 · Cited by 525
Self-citationIntravenous Immune Globulin in Autoimmune and Inflammatory Diseases
Gelfand, E. W. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1009433 · Cited by 495
Jordan, S. C., Tyan, D., Stablein, D., McIntosh, M., Rose, S., Vo, A., Toyoda, M., Davis, C., Shapiro, R., Adey, D., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000145878.92906.9f · Cited by 435
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies
Manwani, D., & Frenette, P. S. (2013) · Blood · doi:10.1182/blood-2013-05-498311 · Cited by 428
Immunoglobulin G glycosylation in aging and diseases
Gudelj, I., Lauc, G., & Pezer, M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.009 · Cited by 408
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
Boruchov, A. M. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24772 · Cited by 377
B CELL IMMUNOBIOLOGY IN DISEASE: Evolving Concepts from the Clinic
Martin, F., & Chan, A. C. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090517 · Cited by 369
Kyogoku, C., Dijstelbloem, H. M., Tsuchiya, N., Hatta, Y., Kato, H., Yamaguchi, A., Fukazawa, T., Jansen, M. D., Hashimoto, H., van de Winkel, J. G. J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10257 · Cited by 332
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
Dalakas, M. C. (2004) · JAMA · doi:10.1001/jama.291.19.2367 · Cited by 329
B‐lymphocyte contributions to human autoimmune disease
Yanaba, K., Bouaziz, J., Matsushita, T., Magro, C. M., St.Clair, E. W., & Tedder, T. F. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00646.x · Cited by 326
Ionescu, L., Byrne, R. N., van Haaften, T., Vadivel, A., Alphonse, R. S., Rey-Parra, G. J., Weissmann, G., Hall, A., Eaton, F., & Thébaud, B. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00144.2011 · Cited by 323
A Novel Role for the IgG Fc Glycan: The Anti-inflammatory Activity of Sialylated IgG Fcs
Anthony, R. M., & Ravetch, J. V. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9405-6 · Cited by 318
Self-citationA review of the current use of rituximab in autoimmune diseases
Gürcan, H. M., Keskin, D. B., Stern, J. N. H., Nitzberg, M. A., Shekhani, H., & Ahmed, A. R. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2008.10.004 · Cited by 314
Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin
Bayry, J., Lacroix-Desmazes, S., Carbonneil, C., Misra, N., Donkova, V., Pashov, A., Chevailler, A., Mouthon, L., Weill, B., Bruneval, P., et al. (2003) · Blood · doi:10.1182/blood-2002-05-1447 · Cited by 306
Bruhns, P., Samuelsson, A., Pollard, J. W., & Ravetch, J. V. (2003) · Immunity · doi:10.1016/s1074-7613(03)00080-3 · Cited by 304
Self-citationIntravenous immunoglobulin in neurology—mode of action and clinical efficacy
Lünemann, J. D., Nimmerjahn, F., & Dalakas, M. C. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.253 · Cited by 301
Clearance of pathological antibodies using biomimetic nanoparticles
Copp, J. A., Fang, R. H., Luk, B. T., Hu, C.-M. J., Gao, W., Zhang, K., & Zhang, L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412420111 · Cited by 296
Nonredundant Roles for B Cell-Derived IL-10 in Immune Counter-Regulation
Madan, R., Demircik, F., Surianarayanan, S., Allen, J. L., Divanovic, S., Trompette, A., Yogev, N., Gu, Y., Khodoun, M., Hildeman, D., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900185 · Cited by 295
Ephrem, A., Chamat, S., Miquel, C., Fisson, S., Mouthon, L., Caligiuri, G., Delignat, S., Elluru, S., Bayry, J., Lacroix-Desmazes, S., et al. (2008) · Blood · doi:10.1182/blood-2007-03-079947 · Cited by 292
Antibody‐mediated modulation of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00910.x · Cited by 285
Self-citationThe antiinflammatory activity of IgG: the intravenous IgG paradox
Nimmerjahn, F., & Ravetch, J. V. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061788 · Cited by 280
Self-citationDesensitization Protocols and Their Outcome
Marfo, K., Lu, A., Ling, M., & Akalin, E. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08140910 · Cited by 272
The pathogenesis of immune thrombocytopaenic purpura
Cooper, N., & Bussel, J. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06024.x · Cited by 272
Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action
NEGI, V.-S., ELLURU, S., SIBÉRIL, S., GRAFF-DUBOIS, S., MOUTHON, L., KAZATCHKINE, M. D., LACROIX-DESMAZES, S., BAYRY, J., & KAVERI, S. V. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9088-9 · Cited by 271
IVIG-mediated effector functions in autoimmune and inflammatory diseases
Galeotti, C., Kaveri, S. V., & Bayry, J. (2017) · International Immunology · doi:10.1093/intimm/dxx039 · Cited by 269
Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases
Li, N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24394 · Cited by 264
Ballow, M. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.10.030 · Cited by 253
Washburn, N., Schwab, I., Ortiz, D., Bhatnagar, N., Lansing, J. C., Medeiros, A., Tyler, S., Mekala, D., Cochran, E., Sarvaiya, H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1422481112 · Cited by 225
Fc Gamma Receptors and Their Role in Antigen Uptake, Presentation, and T Cell Activation
Junker, F., Gordon, J., & Qureshi, O. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01393 · Cited by 219
Mechanisms of disease: The human N-glycome
Lauc, G., Pezer, M., Rudan, I., & Campbell, H. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.10.016 · Cited by 184
“This is confirmed by the finding that the hyper-sialylated Fc fraction, recognized by the DC-SIGN (CD209) receptor, is responsible for the anti-inflammatory property of intravenous immunoglobulins administered at high doses (g/kg) [56,57].”
BackgroundAntibody-based therapies for malaria
Pleass, R. J., & Holder, A. A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1267 · Cited by 182
Mednick, A. J., Feldmesser, M., Rivera, J., & Casadevall, A. (2003) · European Journal of Immunology · doi:10.1002/eji.200323626 · Cited by 128
B cells and autoantibodies: Complex roles in CNS injury
Ankeny, D. P., & Popovich, P. G. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.06.006 · Cited by 116
Polymeric human Fc-fusion proteins with modified effector functions
Mekhaiel, D. N. A., Czajkowsky, D. M., Andersen, J. T., Shi, J., El-Faham, M., Doenhoff, M., McIntosh, R. S., Sandlie, I., He, J., Hu, J., et al. (2011) · Scientific Reports · doi:10.1038/srep00124 · Cited by 85
Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury
Zhang, G., Massaad, C. A., Gao, T., Pillai, L., Bogdanova, N., Ghauri, S., & Sheikh, K. A. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.05.020 · Cited by 38
“Recent studies indicate that modulation of inflammation via innate immune effectors, i.e., FcγRs, could be amechanismof IVIg efficacy in animalmodels of immune arthritis and thrombocytopenic purpura (Anthony et al., 2011; Kaneko et al., 2006; Samuelsson et al., 2001).”
BackgroundDeveloping the IVIG biomimetic, Hexa-Fc, for drug and vaccine applications
Czajkowsky, D. M., Andersen, J. T., Fuchs, A., Wilson, T. J., Mekhaiel, D., Colonna, M., He, J., Shao, Z., Mitchell, D. A., Wu, G., et al. (2015) · Scientific Reports · doi:10.1038/srep09526 · Cited by 38
Glycoengineering Chinese hamster ovary cells: a short history
Donini, R., Haslam, S. M., & Kontoravdi, C. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200840 · Cited by 37
ADAP restraint of STAT1 signaling regulates macrophage phagocytosis in immune thrombocytopenia
Xiong, Y., Li, Y., Cui, X., Zhang, L., Yang, X., & Liu, H. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00881-2 · Cited by 27
Akyol, G. Y., Manaenko, A., Akyol, O., Solaroglu, I., Ho, W. M., Ding, Y., Flores, J., Zhang, J. H., & Tang, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-15455-w · Cited by 25
Clinical immunologic approaches for the treatment of Alzheimer's disease
Solomon, B. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.6.819 · Cited by 22
“The inflammation, initialized by cells bound to the Fc receptors, is then amplified by cellular mediators and activated complement, leading to brain inflammation [61-64].”
BackgroundProduction of Highly Sialylated Monoclonal Antibodies
Raymond, C., Robotham, A., Kelly, J., Lattova, E., Perreault, H., & Durocher, Y. (2012) · Glycosylation · doi:10.5772/51301 · Cited by 20
Metadata
- Authors
- Samuelsson, A., Towers, T. L., & Ravetch, J. V.
- Venue
- Science
- Published
- 2001-01-19
- Volume
- 291
- Issue
- 5503
- Pages
- 484-486
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1964180982
- Cited by
- 1,053
- References
- 22
- FWCI
- 50.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.